JMP Securities initiated coverage on BeiGene Ltd (NASDAQ:BGNE), noting the Chinese biotech firm as a ‘unique investment opportunity.’
The company’s flagship drug, Brukinsa (zanubrutinib), is among the more recent BTK inhibitors to break into a global market projected to hit $12.2 billion by 2031. Three major players dominate this sector, with Johnson & Johnson‘s (NYSE:JNJ) Imbruvica leading the charge, peaking at $8.7 billion in sales in 2021.
Also Read: Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer.
However, competition intensified when AstraZeneca Plc‘s (NASDAQ:AZN) Calquence and Brukinsa entered the market in 2017 and 2019, respectively.
Analyst Reni Benjamin’s confidence in Brukinsa ...
